Local News

• Targeted Genetics realigns product development priorities  Targeted Genetics announced that it has realigned its product development priorities to focus on its ocular and neurological product candidates and its first use of expressed RNAi.
  Targeted Genetics Corporation December 02, 2008  
• Monsanto Company completes acquisitions of CanaVialis and Alellyx  Monsanto announced that it has completed its proposed acquisition of Aly Participacoes, which operates the sugarcane breeding and technology companies, CanaVialis and Alellyx, both of which are based in Brazil.
  Monsanto Company December 02, 2008  
• Monsanto to leverage its technology to enhance yield and economic value for farmers  As farmers in the U.S. are making their initial seed purchase decisions for the 2009 growing season, Monsanto Company plans to discuss the reasons behind its confidence that it can make good on its commitment to more than double its fiscal 2007 gross profit by 2012.
  Monsanto Company December 02, 2008  
• GSK and Theravance announce positive phase 2b results for LABA, `444  GlaxoSmithKline and Theravance announced positive results from the phase 2b study of the novel, long-acting beta agonist (LABA) GW642444 (‘444) in patients with moderate to severe asthma.
  GlaxoSmithKline December 02, 2008  
• ETHICON completes divestiture of Professional Wound Care Business to One Equity Partners  ETHICON, a Johnson & Johnson company, announced that it has completed the divestiture of its Professional Wound Care business to One Equity Partners. Financial terms of the transaction are not being disclosed.
  Johnson & Johnson December 01, 2008  
• Johnson & Johnson announces definitive agreement to acquire Mentor  Johnson & Johnson and Mentor Corporation, a leading supplier of medical products for the global aesthetic market, announced a definitive agreement whereby Mentor will be acquired for approximately $1.07 billion in a cash tender offer.
  Johnson & Johnson December 01, 2008  
• QLT to repurchase up to US$ 50 million of common shares  QLT announced that its Board of Directors has authorized management to proceed with a modified "Dutch Auction" tender offer to purchase a number of shares of its common stock that does not exceed an aggregate purchase price of US$50 million.
  QLT Inc. December 01, 2008  
• FDA accepts Cell Therapeutics' Zevalin sBLA and grants priority review  Cell Therapeutics announced that the FDA has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin(R) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma.
  Cell Therapeutics, Inc. December 01, 2008  
• Cardiome discloses Chairman and CEO's involuntary share sale  Cardiome Pharma disclosed that its Chairman and Chief Executive Officer, Bob Rieder, was recently subject to involuntary margin sales of 45,000 common shares from his direct holding of Cardiome stock.
  Cardiome Pharma Corp. November 28, 2008  
• Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain  Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.
  Eli Lilly and Company November 28, 2008  

   (next 10 articles)